Chemerin reduces vascular nitric oxide/cGMP signalling in rat aorta: A link to vascular dysfunction in obesity?

Clinical Science

Volumn 127, Issue 2, 2014, Pages 111-122

  Neves, Karla Bianca ^a   Lobato, Núbia S ^b   Lopes, Rhéure Alves Moreira ^a   Filgueira, Fernando P ^a   Zanotto, Camila Ziliotto ^b   Oliveira, Ana Maria ^a   Tostes, Rita C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Adipokine; Chemerin; NO cGMP signalling; Vascular dysfunction

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLCHOLINE; CHEMERIN; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TEMPOL; TETRAHYDROBIOPTERIN; TIRON; ADIPOCYTOKINE; NITRIC OXIDE SYNTHASE;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BLOOD VESSEL; ENZYME ACTIVATION; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION; VASCULAR DISEASE; VASCULAR RING; VASCULARIZATION; VASODILATATION; WESTERN BLOTTING; WISTAR RAT; ANIMAL; DRUG EFFECTS; METABOLISM; THORACIC AORTA; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ADIPOKINES; ANIMALS; AORTA, THORACIC; CYCLIC GMP; ENDOTHELIUM, VASCULAR; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OBESITY; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; SUPEROXIDES;

EID: 84897511110     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130286     Document Type: Article

References (56)

1. Ahima R. S. (2006) Adipose tissue as an endocrine organ. Obesity 14 (Suppl. 5), 242S-249S.
2. Brandes R. P. (2007) The fatter the better? Perivascular adipose tissue attenuates vascular contraction through different mechanisms. Br. J. Pharmacol. 151, 303-304.
3. Matsuzawa Y. (2005) White adipose tissue and cardiovascular disease. Best Pract. Res. Clin. Endocrinol. Metab. 19, 637-647.
4. Ernst M. C. and Sinal C. J. (2010) Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol. Metab. 21, 660-667.
5. Wittamer V., Gregoire F., Robberecht P., Vassart G., Communi D. and Parmentier M. (2004) The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J. Biol. Chem. 279, 9956-9962.
6. Watts S. W., Dorrance A. M., Penfold M. E., Rourke J. L., Sinal C. J., Seitz B., Sullivan T. J., Charvat T. T., Thompson J. M., Burnett R. and Fink G. D. (2013) Chemerin connects fat to arterial contraction. Arterioscler. Thromb. Vasc. Biol. 33, 1320-1328.
7. Bozaoglu K., Bolton K., McMillan J., Zimmet P., Jowett J., Collier G., Walder K. and Segal D. (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148, 4687-4694.
8. Ernst M. C., Haidl I. D., Zuniga L. A., Dranse H. J., Rourke J. L., Zabel B. A., Butcher E. C. and Sinal C. J. (2012) Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology 153, 672-682.
9. Bozaoglu K., Segal D., Shields K. A., Cummings N., Curran J. E., Comuzzie A. G., Mahaney M. C., Rainwater D. L., VandeBerg J. L., MacCluer J. W. et al. (2009) Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J. Clin. Endocrinol. Metab. 94, 3085-3088.
10. Sell H., Divoux A., Poitou C., Basdevant A., Bouillot J. L., Bedossa P., Tordjman J., Eckel J. and Clement K. (2010) Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 95, 2892-2896.
11. Gao X., Mi S., Zhang F., Gong F., Lai Y., Gao F., Zhang X., Wang L. and Tao H. (2011) Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovasc. Diabetol. 10, 87.
12. Spiroglou S. G., Kostopoulos C. G., Varakis J. N. and Papadaki H. H. (2010) Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J. Atheroscler. Thromb. 17, 115-130.
13. Hah Y. J., Kim N. K., Kim M. K., Kim H. S., Hur S. H., Yoon H. J., Kim Y. N. and Park K. G. (2011) Relationship between chemerin levels and cardiometabolic parameters and degree of coronary stenosis in korean patients with coronary artery disease. Diabetes Metab. J. 35, 248-254.
14. Lobato N. S., Neves K. B., Filgueira F. P., Fortes Z. B., Carvalho M. H., Webb R. C., Oliveira A. M. and Tostes R. C. (2012) The adipokine chemerin augments vascular reactivity to contractile stimuli via activation of the MEK-ERK1/2 pathway. Life Sci. 91, 600-606.
15. Sausbier M., Schubert R., Voigt V., Hirneiss C., Pfeifer A., Korth M., Kleppisch T., Ruth P. and Hofmann F. (2000) Mechanisms of NO/cGMP-dependent vasorelaxation. Circ. Res. 87, 825-830.
16. Peiro C., Redondo J., Rodriguez-Martinez M. A., Angulo J., Marin J. and Sanchez-Ferrer C. F. (1995) Influence of endothelium on cultured vascular smooth muscle cell proliferation. Hypertension 25, 748-751.
17. Handa P., Tateya S., Rizzo N. O., Cheng A. M., Morgan-Stevenson V., Han C. Y., Clowes A. W., Daum G., O'Brien K. D., Schwartz M. W. et al. (2011) Reduced vascular nitric oxide-cGMP signaling contributes to adipose tissue inflammation during high-fat feeding. Arterioscler. Thromb. Vasc. Biol. 31, 2827-2835.
18. Rizzo N. O., Maloney E., Pham M., Luttrell I., Wessells H., Tateya S., Daum G., Handa P., Schwartz M. W. and Kim F. (2010) Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding. Arterioscler. Thromb. Vasc. Biol. 30, 758-765.
19. Melichar V. O., Behr-Roussel D., Zabel U., Uttenthal L. O., Rodrigo J., Rupin A., Verbeuren T. J., Kumar H. S. A. and Schmidt H. H. (2004) Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 101, 16671-16676.
20. Giachini F. R., Carneiro F. S., Lima V. V., Carneiro Z. N., Carvalho M. H., Fortes Z. B., Webb R. C. and Tostes R. C. (2008) Pyk2 mediates increased adrenergic contractile responses in arteries from DOCA-salt mice. J. Am. Soc. Hypertens. 2, 431-438.
21. Zabel B. A., Zuniga L., Ohyama T., Allen S. J., Cichy J., Handel T. M. and Butcher E. C. (2006) Chemoattractants, extracellular proteases and the integrated host defense response. Exp. Hematol. 34, 1021-1032.
22. Cai S., Alp N. J., McDonald D., Smith I., Kay J., Canevari L., Heales S. and Channon K. M. (2002) GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc. Res. 55, 838-849.
23. Pernomian L., Santos Gomes M., Baraldi Araujo Restini C., Naira Zambelli Ramalho L., Renato Tirapelli C. and Maria de Oliveira A. (2012) The role of reactive oxygen species in the modulation of the contraction induced by angiotensin II in carotid artery from diabetic rat. Eur. J. Pharmacol. 678, 15-25.
24. Pereira A. C., Olivon V. C. and de Oliveira A. M. (2010) Impaired calcium influx despite hyper-reactivity in contralateral carotid following balloon injury: eNOS involvement. Eur. J. Pharmacol. 642, 121-127.
25. Giachini F. R., Lima V. V., Carneiro F. S., Tostes R. C. and Webb R. C. (2011) Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1. Hypertension 57, 655-663.
26. Castro M. M., Rizzi E., Rascado R. R., Nagassaki S., Bendhack L. M. and Tanus-Santos J. E. (2004) Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur. J. Pharmacol. 498, 189-194.
27. Chignalia A. Z., Schuldt E. Z., Camargo L. L., Montezano A. C., Callera G. E., Laurindo F. R., Lopes L. R., Avellar M. C., Carvalho M. H., Fortes Z. B. et al. (2012) Testosterone induces vascular smooth muscle cell migration by NADPH oxidase and c-Src-dependent pathways. Hypertension 59, 1263-1271.
28. Cosentino F. and Luscher T. F. (1999) Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc. Res. 43, 274-278.
29. Stuehr D. J. and Griffith O. W. (1992) Mammalian nitric oxide synthases. Adv. Enzymol. Relat. Areas Mol. Biol. 65, 287-346.
30. Vila E. and Salaices M. (2005) Cytokines and vascular reactivity in resistance arteries. Am. J. Physiol. Heart Circ. Physiol. 288, H1016-H1021.
31. Dong B., Ji W. and Zhang Y. (2011) Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern. Med. 50, 1093-1097.
32. Parlee S. D., Ernst M. C., Muruganandan S., Sinal C. J. and Goralski K. B. (2010) Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-α. Endocrinology 151, 2590-2602.
33. Ernst M. C., Issa M., Goralski K. B. and Sinal C. J. (2010) Chemerin exacerbates glucose intolerance in mouse models of obesity and diabetes. Endocrinology 151, 1998-2007.
34. Li H., Wallerath T., Munzel T. and Forstermann U. (2002) Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide 7, 149-164.
35. Ozaki M., Kawashima S., Yamashita T., Hirase T., Namiki M., Inoue N., Hirata K., Yasui H., Sakurai H., Yoshida Y. et al. (2002) Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J. Clin. Invest. 110, 331-340.
36. Cosentino F., Patton S., d'Uscio L. V., Werner E. R., Werner-Felmayer G., Moreau P., Malinski T. and Luscher T. F. (1998) Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J. Clin. Invest. 101, 1530-1537.
37. Forstermann U. (2010) Nitric oxide and oxidative stress in vascular disease. Eur. J. Physiol. 459, 923-939.
38. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., Skatchkov M., Thaiss F., Stahl R. A., Warnholtz A. et al. (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88, E14-E22.
39. Pieper G. M. (1997) Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J. Cardiovasc. Pharmacol. 29, 8-15.
40. Wang S., Xu J., Song P., Wu Y., Zhang J., Chul Choi H. and Zou M. H. (2008) Acute inhibition of guanosine triphosphate cyclohydrolase 1 uncouples endothelial nitric oxide synthase and elevates blood pressure. Hypertension 52, 484-490.
41. Werner-Felmayer G., Werner E. R., Fuchs D., Hausen A., Reibnegger G., Schmidt K., Weiss G. and Wachter H. (1993) Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J. Biol. Chem. 268, 1842-1846.
42. Huang A., Zhang Y. Y., Chen K., Hatakeyama K. and Keaney, Jr J. F. (2005) Cytokine-stimulated GTP cyclohydrolase I expression in endothelial cells requires coordinated activation of nuclear factor-κB and Stat1/Stat3. Circ. Res. 96, 164-171.
43. Katusic Z. S., Stelter A. and Milstien S. (1998) Cytokines stimulate GTP cyclohydrolase I gene expression in cultured human umbilical vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18, 27-32.
44. Creager M. A., Luscher T. F., Cosentino F. and Beckman J. A. (2003) Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy: Part I. Circulation 108, 1527-1532.
45. Meurer S., Pioch S., Pabst T., Opitz N., Schmidt P. M., Beckhaus T., Wagner K., Matt S., Gegenbauer K., Geschka S. et al. (2009) Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ. Res. 105, 33-41.
46. Friebe A., Mergia E., Dangel O., Lange A. and Koesling D. (2007) Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc. Natl. Acad. Sci. U.S.A. 104, 7699-7704.
47. Kass D. A., Takimoto E., Nagayama T. and Champion H. C. (2007) Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc. Res. 75, 303-314.
48. Teravainen T. L., Mervaala E. M., Porsti I., Laakso J., Vapaatalo H. and Karppanen H. (1997) Influence of age and dietary sodium on the cardiovascular and renal effects of ramipril in spontaneously hypertensive rats. Methods Find. Exp. Clin. Pharmacol. 19, 311-321.
49. Preik M., Kelm M., Feelisch M. and Strauer B. E. (1996) Impaired effectiveness of nitric oxide-donors in resistance arteries of patients with arterial hypertension. J. Hypertens. 14, 903-908.
50. Sayed N., Baskaran P., Ma X., van den Akker F. and Beuve A. (2007) Desensitization of soluble guanylyl cyclase, the NO receptor, by S-nitrosylation. Proc. Natl. Acad. Sci. U.S.A. 104, 12312-12317.
51. Schramm A., Matusik P., Osmenda G. and Guzik T. J. (2012) Targeting NADPH oxidases in vascular pharmacology. Vasc. Pharmacol. 56, 216-231.
52. Youn J. Y., Gao L. and Cai H. (2012) The p47phox- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes. Diabetologia 55, 2069-2079.
53. Chalupsky K. and Cai H. (2005) Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 102, 9056-9061.
54. Kaur J., Adya R., Tan B. K., Chen J. and Randeva H. S. (2010) Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem. Biophys. Res. Commun. 391, 1762-1768.
55. Monnier J., Lewen S., O'Hara E., Huang K., Tu H., Butcher E. C. and Zabel B. A. (2012) Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells. J. Immunol. 189, 956-967.
56. Yamawaki H., Kameshima S., Usui T., Okada M. and Hara Y. (2012) A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem. Biophys. Res. Commun. 423, 152-157.